1
关注
1027
浏览

How should design spaceverification approach be addressed in the pharmaceutical quality system?

您还未登录!暂时最多只可查看 1 条回答

登录! 还没有账号?去注册

kk444555 一阶会员 用户来自于: 广东省深圳市
2023-10-17 23:01

FDA recommends that firms have a writtenplan for when and how to evaluate the need for design space verification undertheir pharmaceutical quality system. FDA’s expectation is that such plans for designspace verification be available at the manufacturing site. Additionally, it canbe beneficial to the review of the application for the applicant to include inthe initial submission a high-level overview of the plan for design spaceverification over the product life cycle.

FDA 建议公司制定书面计划,以说明何时以及如何在其药品质量体系下评估设计空间验证的需要。FDA的期望是在生产现场提供此类设计空间验证计划。此外,对于申请人的申请审查,在最初提交的申请中包含产品生命周期内设计空间验证计划的高级概述可能是有益的。


关于作者

问题动态

发布时间
2023-10-17 23:01
更新时间
2023-10-17 23:01
关注人数
1 人关注

相关问题

How to select EMC test samples?
How do the new requirements affect importers of medicinal products?
Should personnel be trained in preventing and detecting data integrity issues
How is a design space initiallydeveloped and verified at commercial scale?
How can a design space beverified at commercial scale?
How can limits for cleaning purposes be established?
How should blank forms be controlled?
How are sub-batches obtained and labelled?
How should manufacturers use the HBELs?
What is the purpose of design spaceverification at commercial scale?